Fujifilm beefs up US biologics capacity with $300M Texas outlay, corrals 150 new jobsnews2021-12-14T15:20:07+00:00December 14th, 2021|Fierce Pharma|
CSL to buy Vifor for $11.7B in biopharma’s largest M&A deal this yearnews2021-12-14T14:37:43+00:00December 14th, 2021|Fierce Pharma|
Samsung Biologics, AstraZeneca expand manufacturing partnership to add COVID and cancer therapiesnews2021-12-14T13:42:39+00:00December 14th, 2021|Fierce Pharma|
Idorsia hoping to make its dreams come true with a new insomnia alliancenews2021-12-14T09:28:40+00:00December 14th, 2021|Fierce Pharma|
CanSino taps Aerogen for development, commercial supply of inhaled COVID-19 vaccine hopefulnews2021-12-13T21:00:01+00:00December 13th, 2021|Fierce Pharma|
Viatris gets shot to shed infringement claims in long-running patent kerfuffle on AstraZeneca’s Symbicortnews2021-12-13T18:18:50+00:00December 13th, 2021|Fierce Pharma|
Novo Nordisk, underway with key launches, reveals $2.58B manufacturing investmentnews2021-12-13T16:20:58+00:00December 13th, 2021|Fierce Pharma|
Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plannews2021-12-13T15:55:46+00:00December 13th, 2021|Fierce Pharma|
Oxford Biomedica, Novartis extend lentiviral vector supply deal for CAR-T drugsnews2021-12-13T15:29:41+00:00December 13th, 2021|Fierce Pharma|
ASH: Roche’s Polivy set to unlock $2B market in newly diagnosed lymphoma with practice-changing datanews2021-12-13T15:17:04+00:00December 13th, 2021|Fierce Pharma|
